Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136461 · ClinicalTrials.gov registry record · Phase 2
A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00136461 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT00136461, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of the combination of all-trans retinoic acid in combination with one of two schedules of Bryostatin 1 in patients with myelodysplasia and acute myelogenous leukemia.
Interventions
- DRUG All-trans retinoic acid
- DRUG Bryostatin 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1997-05 |
| Est. Completion | 2000-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136461
The ClinicalTrials.gov registry entry for NCT00136461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which All-trans retinoic acid is the first listed.
NCT00136461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00136461 about?
NCT00136461 is a clinical study titled "A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)". The purpose of this study is to assess the effects of the combination of all-trans retinoic acid in combination with one of two schedules of Bryostatin 1 in patients with myelodysplasia and acute myelogenous leukemia.
What is the current status of trial NCT00136461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1997-05. Estimated completion is 2000-08.
What interventions are being tested in trial NCT00136461?
The interventions under investigation include: All-trans retinoic acid (DRUG), Bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00136461?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.